Exact Sciences strengthened its pipeline capabilities with its acquisition of Biomatrica, a provider of biological sample preservation technology, the company announced today.

“To detect cancer at its earliest stages, you need the right team backed by the highest-quality science, data and materials,” Exact Sciences CEO Kevin Conroy said in a statement. “Biomatrica’s preservation chemistry ensures the reliability of results, even when blood and other biological samples undergo the stresses of shipping and storage.”

According to a release, Exact Sciences intends to use Biomatrica’s proprietary technology to support the ongoing and future development of its own blood-based cancer detection tests.

Financial terms of the deal were not disclosed.

Biomatrica was founded in 2004 and is headquartered in San Diego.